Last C$0.03 CAD
Change Today 0.00 / 0.00%
Volume 0.0
CYX On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 3:59 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

calyx bio-ventures inc (CYX) Snapshot

Open
C$0.03
Previous Close
C$0.03
Day High
C$0.03
Day Low
C$0.03
52 Week High
01/6/14 - C$0.27
52 Week Low
12/16/14 - C$0.02
Market Cap
960.0K
Average Volume 10 Days
46.5K
EPS TTM
C$-0.06
Shares Outstanding
38.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CALYX BIO-VENTURES INC (CYX)

Related News

No related news articles were found.

calyx bio-ventures inc (CYX) Related Businessweek News

No Related Businessweek News Found

calyx bio-ventures inc (CYX) Details

Calyx Bio-Ventures Inc. owns a portfolio of patents related to modifying and engineering agricultural crop traits in Canada. Its technologies include Engineered Trait Loci (ETL) Technology that enhances crops; and REM technology. The company also holds rights to use the artificial chromosome expression (ACE) system for gene therapy and transgenics. In addition, it has interest in and licenses a technology to Agrisoma Biosciences Inc. that uses ETL technology to commercialize a suite of oil quality and crop improvement traits for use in energy feedstock crops. Calyx Bio-Ventures Inc. is headquartered in Vancouver, Canada.

calyx bio-ventures inc (CYX) Top Compensated Officers

President, Chief Executive Officer, Director,...
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

calyx bio-ventures inc (CYX) Key Developments

Calyx Bio-Ventures Inc., Annual General Meeting, Dec 16, 2014

Calyx Bio-Ventures Inc., Annual General Meeting, Dec 16, 2014., at 14:00 Pacific Standard Time. Location: Suite 2600, Oceanic Plaza. Agenda: To fix the number of directors at three; to elect directors for the ensuing year; to appoint Dale Matheson Carr - Hilton Labonte LLP, as auditor of the company for the ensuing year; to authorize the directors to determine the remuneration to be paid to the auditor; to confirm the company's stock option plan; and to transact such other business as may properly be put before the meeting.

Calyx Bio-Ventures Inc. Announces Change of Auditor

Calyx Bio-Ventures Inc. announced that it has changed auditors from Ernst & Young, LLP to Dale Matheson Carr-Hilton LaBonte LLP.

Calyx Bio-Ventures Inc. Announces Board Changes

Calyx Bio-Ventures Inc. announced that Derek Penner has joined the company's board of directors effective from January 22, 2014. Mr. Penner brings extensive global agriculture commercialization, potential partnership relationships and executive leadership experience to Calyx, having previously served as President of Monsanto Canada. Additionally, the company announced the resignation of Richard Whittall from the board of directors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYX:CN C$0.03 CAD 0.00

CYX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYX.
View Industry Companies
 

Industry Analysis

CYX

Industry Average

Valuation CYX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CALYX BIO-VENTURES INC, please visit www.chromos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.